VivoSim Labs, Inc. (VIVS)
NASDAQ: VIVS · Real-Time Price · USD
1.835
+0.005 (0.27%)
At close: Jun 5, 2025, 4:00 PM
1.870
+0.035 (1.91%)
After-hours: Jun 5, 2025, 7:38 PM EDT
VivoSim Labs Employees
As of March 31, 2024, VivoSim Labs had 20 total employees, including 12 full-time and 8 part-time employees. The number of employees decreased by 4 or -16.67% compared to the previous year.
Employees
20
Change (1Y)
-4
Growth (1Y)
-16.67%
Revenue / Employee
$6,100
Profits / Employee
-$619,250
Market Cap
3.27M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
VIVS News
- 16 days ago - I Missed The Quantum Rally - I Won't Miss The Next One - Seeking Alpha
- 23 days ago - VivoSim's NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference - GlobeNewsWire
- 4 weeks ago - VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference - GlobeNewsWire
- 6 weeks ago - VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market - GlobeNewsWire
- 6 weeks ago - VivoSim to Carry Forward Organovo 3D Bioprinting - GlobeNewsWire
- 2 months ago - Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements - GlobeNewsWire
- 2 months ago - Organovo Provides Business Update - GlobeNewsWire
- 2 months ago - Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company - GlobeNewsWire